Fulltext

Pretreatment thrombocytosis : A prognostic marker for oral squamous cell carcinoma?

Kargus, Steffen ; Weber, Franz ; Luebbers, Heinz ; Zemann, Wolfgang ; Graetz, Klaus ; Kruse, Astrid

In: Oral and Maxillofacial Surgery, 2012, vol. 16, no. 2, p. 197-200

Add to personal list
    Title
    • Pretreatment thrombocytosis
      A prognostic marker for oral squamous cell carcinoma?
    Author
    • Kargus, Steffen. Department of Craniomaxillofacial and Oral Surgery, University Hospital Zurich, Frauenklinikstr. 24, 8091, Zurich, Switzerland
    • Weber, Franz. Department of Craniomaxillofacial and Oral Surgery, University Hospital Zurich, Frauenklinikstr. 24, 8091, Zurich, Switzerland
    • Luebbers, Heinz. Department of Craniomaxillofacial and Oral Surgery, University Hospital Zurich, Frauenklinikstr. 24, 8091, Zurich, Switzerland
    • Zemann, Wolfgang. Department of Craniomaxillofacial and Oral Surgery, University Hospital Zurich, Frauenklinikstr. 24, 8091, Zurich, Switzerland
    • Graetz, Klaus. Department of Craniomaxillofacial and Oral Surgery, University Hospital Zurich, Frauenklinikstr. 24, 8091, Zurich, Switzerland
    • Kruse, Astrid. Department of Craniomaxillofacial and Oral Surgery, University Hospital Zurich, Frauenklinikstr. 24, 8091, Zurich, Switzerland
    Document Type
    • Postprint
    OAI-PMH Identifier
    • oai:doc.rero.ch:309776
    Summary
    Purpose: Thrombocytosis associated with poorer prognoses seems to be a frequent preoperative finding in different kind of cancers. The aim of the present study was to evaluate whether thrombocytosis can be used as a prognostic marker for oral squamous cell carcinoma (SCC). Methods: Altogether, 288 patients with oral SCC were considered, as well as all platelet counts between 1 and 5days prior to surgical treatment, recurrence rate, and lymph node metastasis. The minimum follow-up time was 12months. Results: The mean preoperative thrombocyte score of the patients who received surgery was 259.55 ± 83.8 Tsd/μl; 273 out of 288 patients were in the normal thrombocyte range, and 12 had a thrombocytosis. From 51 patients with recurrence, three were in the thrombocytosis group, and 45 patients with recurrence were in the normal thrombocyte range. Conclusion: The present results do not confirm that thrombocytosis can be seen as marker for poor tumor prognosis